An Evaluative Study Of Serum Adiponectin And Lipid Profile Level In Newly Diagnosed Diabetic Patients In Garhwal Region, Uttarakhand.
DOI:
https://doi.org/10.53555/ejac.v18i1.1065Keywords:
Type 2 Diabetes, Lipid Profile and serum adiponectin.Abstract
Background: Numerous lipids and lipoprotein imbalances in the blood, such as low incidence of HDL cholesterol, a high incidence of small, dense LDL cholesterol, and high triglycerides are associated with type 2 diabetes. Many people have type 2 diabetes issue while having high LDL cholesterol levels. These modifications are also a component of the metabolic syndrome, often known as the insulin resistance syndrome, which is frequently associated with type 2 diabetes in adults
Aim and Objectives: To evaluate the level of serum adiponectin and lipid profile in newly diagnosed type 2 diabetes mellitus cases and find out the association of serum adiponectin with lipid profile in them.
Methods: The present study takes place in Garhwal region Uttarakhand. A total number of 384 subjects (including 192 diabetic subjects as cases and 192 subject as control group) have been selected. The cases were newly diagnosed type 2 Diabetes mellitus. Patients with chronic illness, pregnancy, alcoholism, Type 1 diabetes were excluded from the study. Both genders, male and female with age group 30 -70 years were selected. Lipid profile and adiponectin were estimated for both groups.
Result: In our study we have observed increased levels of serum cholesterol, triglycerides, LDL and VLDL cholesterol in Diabetic cases as compared to control group, which was statistically significant (p value <0.01). HDL level was lower in diabetic cases as compared to control group, which was also statistically significant (p value <0.01). The level of serum adiponectin was lower in newly diagnosed subjects as compared to control group, which was also statistically significant (p value <0.01).
Conclusion: Adiponectin can be used as an important clinical biomarker and can be used as cut off to predict the occurrence of type 2 diabetes mellitus.
References
Aleidi, S., Issa, A., Bustanji, H., Khalil, M., & Bustanji, Y. (2015). Adiponectin serum levels correlate with insulin resistance in type 2 diabetic patients. Saudi Pharmaceutical Journal, 23(3), 250–256.https://doi.org/10.1016/j.jsps.2014.11.011
Arshag D Mooradian. (2009). Dyslipidemia in type 2 diabetes mellitus. National Clinical Practice Endocrinology Metabolism, 3(5). https://doi.org/10.1038/ncpendmet1066
Bazmandegan, G., Abbasifard, M., Nadimi, A. E., Alinejad, H., & Kamiab, Z. (2023). Cardiovascular risk factors in diabetic patients with and without metabolic syndrome: a study based on the Rafsanjan cohort study. Scientific Reports, 13(1). https://doi.org/10.1038/s41598-022-27208-5
Bhowmik, B., Siddiquee, T., Mujumder, A., Afsana, F., Ahmed, T., Mdala, I. A., Nayla, N. C., Khan, A. K. A., Hussain, A., Holmboe-Ottesen, G., & Omsland, T. K. (2018). Serum lipid profile and its association with diabetes and prediabetes in a rural Bangladeshi population. International Journal of Environmental Research and Public Health, 15(9). https://doi.org/10.3390/ijerph15091944
Carlos G Santos-Gallego, & Robert S Rosenson. (2014). Role of HDL in those with diabetes. Curr Cardiol Rep, 9(16).
Fagerberg, B., Kellis, D., Bergström, G., & Behre, C. J. (2011). Adiponectin in relation to insulin sensitivity and insulin secretion in the development of type 2 diabetes: A prospective study in 64-year-old women. Journal of Internal Medicine, 269(6), 636–643. https://doi.org/10.1111/j.1365-2796.2010.02336.x
Feingold, K. R. (2023). Dyslipidemia in Patients with Diabetes. In A service of the National Library of Medicine, National Institutes of Health. (p. 07).
Gagel, A., Zghyer, F., Samuel, C., & Martin, S. S. (2022). What is the Optimal Low-Density Lipoprotein Cholesterol? In Medical Clinics of North America (Vol. 106, Issue 2, pp. 285–298). W.B. Saunders. https://doi.org/10.1016/j.mcna.2021.11.005
Gil-Campos, M., Cañete, R., & Gil, A. (2004). Adiponectin, the missing link in insulin resistance and obesity. In Clinical Nutrition (Vol. 23, Issue 5, pp. 963–974). https://doi.org/10.1016/j.clnu.2004.04.010
Heiker, J. T., Kosel, D., & Beck-Sickinger, A. G. (2010). Molecular mechanisms of signal transduction via adiponectin and adiponectin receptors. Walter de Gruyter Berlin New York. https://doi.org/10.1515/bc.2010.104/html
Hong, X., Zhang, X., You, L., Li, F., Lian, H., Wang, J., Mao, N., Ren, M., Li, Y., Wang, C., & Sun, K. (2023). Association between adiponectin and newly diagnosed type 2 diabetes in population with the clustering of obesity, dyslipidaemia and hypertension: a cross-sectional study. BMJ Open, 13(2). https://doi.org/10.1136/bmjopen-2021-060377
J. Larry Jameson. (2010). HARRISON’S Endocrinology (Eugene Braunwald, Anthony S. Fauci, Dennis L. Kasper, Stephen L. Hauser, Dan L. Longo, & Joseph Loscalzo, Eds.; 2nd ed.). Mc Graw Hill Medical.
Jameson J. Larry, Fauci S. Anthony, Kasper L. Dennis, Hauser L. Stephen, Longo L. Dan, & Loscalzo Joseph. (2018). Harrison’s Principles of Internal Medicine (T. R. Harrison, W. R. Resnick, M. M. Wintrobe, G. W. Thorn, R. D. Adams, P. B. Beeson, Jr. I. L. Bennett, E. Braunwald, K. J. Isselbacher, R. G. Petersdorf, J. L. Jameson, D. L. Longo, S. L. Hauser, D. L. Kasper, R. Root, A. S. Fauci, J. B. Martin, J. D. Wilson, & J. Loscalzo, Eds.; 20th ed., Vol. 1). McGraw-Hill Education.
Joshi, S. R., Anjana, R. M., Deepa, M., Pradeepa, R., Bhansali, A., Dhandania, V. K., Joshi, P. P., Unnikrishnan, R., Nirmal, E., Subashini, R., Madhu, S. V., Rao, P. V., Das, A. K., Kaur, T., Shukla, D. K., & Mohan, V. (2014). Prevalence of dyslipidemia in urban and rural India: The ICMR-INDIAB study. PLoS ONE, 9(5). https://doi.org/10.1371/journal.pone.0096808
Kant, R., & Khapre, M. (2019). Profile of metabolic syndrome in newly detected hypertensive patients in India: An hospital-based study. International Journal of Applied and Basic Medical Research, 9(1), 32. https://doi.org/10.4103/ijabmr.ijabmr_108_18
Prasad, M., Jayaraman, S., Eladl, M. A., El-Sherbiny, M., Abdelrahman, M. A. E., Veeraraghavan, V. P., Vengadassalapathy, S., Umapathy, V. R., Jaffer Hussain, S. F., Krishnamoorthy, K., Sekar, D., Palanisamy, C. P., Mohan, S. K., & Rajagopal, P. (2022). A Comprehensive Review on Therapeutic Perspectives of Phytosterols in Insulin Resistance: A Mechanistic Approach. In Molecules (Vol. 27, Issue 5). MDPI. https://doi.org/10.3390/molecules27051595
Rana, J. S., Liu, J. Y., Moffet, H. H., Solomon, M. D., Go, A. S., Jaffe, M. G., & Karter, A. J. (2015). Metabolic Dyslipidemia and Risk of Coronary Heart Disease in 28,318 Adults with Diabetes Mellitus and Low-Density Lipoprotein Cholesterol <100 mg/dl. American Journal of Cardiology, 116(11), 1700–1704. https://doi.org/10.1016/j.amjcard.2015.08.039
Sheng, T., & Yang, K. (2008). Adiponectin and its association with insulin resistance and type 2 diabetes. Journal of Genetics and Genomics, 35(6), 321–326. https://doi.org/10.1016/S1673-8527(08)60047-8
Simpson, F., & Whitehead, J. P. (2010). Adiponectin-It’s all about the modifications. In International Journal of Biochemistry and Cell Biology (Vol. 42, Issue 6, pp. 785–788). https://doi.org/10.1016/j.biocel.2009.12.021
Thakur, S., Raina, S., Thakur, S., Negi, P., & Verma, B. (2013). Prevalence of metabolic syndrome among newly diagnosed hypertensive patients in the hills of Himachal Pradesh, India. Indian Journal of Endocrinology and Metabolism, 17(4), 723. https://doi.org/10.4103/2230-8210.113768
Von Frankenberg, A. D., Do Nascimento, F. V., Gatelli, L. E., Nedel, B. L., Garcia, S. P., De Oliveira, C. S., Saddi-Rosa, P., Reis, A. F., Canani, L. H., & Gerchman, F. (2014). Major components of metabolic syndrome and adiponectin levels: A cross-sectional study. Diabetology and Metabolic Syndrome, 6(1). https://doi.org/10.1186/1758-5996-6-26
Downloads
Published
Versions
- 05-03-2025 (4)
- 05-03-2025 (2)
- 25-12-2023 (1)
